Ignite Creation Date:
2024-05-06 @ 7:05 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05891964
Status:
COMPLETED
Last Update Posted:
2023-06-07
First Post:
2023-03-22
Brief Title:
Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital
Sponsor:
Jinnah Postgraduate Medical Centre
Organization:
Jinnah Postgraduate Medical Centre
Study Overview
Official Title:
Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Psoriasis is one of the most common immune-mediated inflammatory disorders characterized by a chronic course It affects approximately 2-3 of the worlds population Psoriasis may be provoked by environmental factors in patients with genetic predispositions Psoriasis is phenotypically characterized by thickened red scaly plaques and systemic inflammation it is also associated with multiple comorbidities such as cardiovascular disease stroke hypertension metabolic diseases chronic kidney disease and joint destruction Psoriasis is pathogenically driven by proinflammatory cytokines and mediated by T and dendritic cells Inflammatory myeloid dendritic cells release interleukin IL 23 and IL-12 to activate IL-17-producing T cells Th1 cells and Th22 cells to produce psoriatic cytokines like IL-17 interferon IFN γ TNF and IL-22 These cytokines mediate the effects on keratinocytes Secukinumab is a recombinant human monoclonal antibody that specifically binds to a proinflammatory cytokine released by T-helper-17 Th17 cells IL-17A It blocks its binding with IL-17R and the expression of cytokines This blockade normalizes the inflammatory processes and combats epidermal hyperproliferation T-cell infiltration and exaggerated expression of pathogenic genes
Detailed Description:
Plaque psoriasis is a chronic autoimmune skin disorder characterized by the formation of thick scaly plaques on the skin surface It affects millions of individuals worldwide and significantly impacts their quality of life While several treatment options exist a substantial number of patients with moderate to severe plaque psoriasis fail to achieve satisfactory results or experience intolerable side effects with conventional therapies
Psoriasis is pathogenically driven by proinflammatory cytokines and mediated by T cells and dendritic cells In recent years the advent of biologic agents targeting specific immune pathways has revolutionized the management of psoriasis Secukinumab a fully human monoclonal antibody that selectively inhibits interleukin-17A has shown promising results in randomized controlled trials and real-world studies However there remains a need to assess the real-world effectiveness and safety of Secukinumab in routine clinical practice particularly in patients with moderate to severe plaque psoriasis who may have diverse characteristics and treatment histories
This observational study aims to evaluate the real-world effectiveness and safety of Secukinumab in patients with moderate to severe plaque psoriasis By collecting data from a diverse patient population in routine clinical settings we aim to provide valuable insights into the outcomes and experiences of patients receiving Secukinumab outside the controlled environment of clinical trials
Psoriasis is pathogenically driven by proinflammatory cytokines and mediated by T cells and dendritic cells In recent years the advent of biologic agents targeting specific immune pathways has revolutionized the management of psoriasis Secukinumab a fully human monoclonal antibody that selectively inhibits interleukin-17A has shown promising results in randomized controlled trials and real-world studies However there remains a need to assess the real-world effectiveness and safety of Secukinumab in routine clinical practice particularly in patients with moderate to severe plaque psoriasis who may have diverse characteristics and treatment histories
This observational study aims to evaluate the real-world effectiveness and safety of Secukinumab in patients with moderate to severe plaque psoriasis By collecting data from a diverse patient population in routine clinical settings we aim to provide valuable insights into the outcomes and experiences of patients receiving Secukinumab outside the controlled environment of clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None